celecoxib has been researched along with Refractory Depression in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Halaris, A | 2 |
| Cantos, A | 1 |
| Johnson, K | 1 |
| Hakimi, M | 1 |
| Sinacore, J | 1 |
| Murata, S | 1 |
| Murphy, M | 1 |
| Hoppensteadt, D | 1 |
| Fareed, J | 1 |
| Welborn, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers[NCT01479829] | Phase 4 | 88 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for celecoxib and Refractory Depression
| Article | Year |
|---|---|
Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Bipolar Disorder; Celecoxib; | 2020 |
Effects of adjunctive inflammatory modulation on IL-1β in treatment resistant bipolar depression.
Topics: Bipolar Disorder; Celecoxib; Citalopram; Depressive Disorder, Treatment-Resistant; Humans; Interleuk | 2020 |